$ONCS News
Last published 3y ago
- 3y agoONCSOncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesPR NewswireEWING, N.J. and SAN DIEGO, May 18, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral
- 3y agoONCSOncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesPR NewswireEWING, N.J. and SAN DIEGO, May 16, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral
- 3y agoONCSOncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical programPR NewswireEWING, N.J. and SAN DIEGO, May 16, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the Company or OncoSec), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the
- 3y agoONCSOncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL ProgramPR NewswireEWING, N.J. and SAN DIEGO, April 27, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the Company or OncoSec), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate
- 3y agoONCSOncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesPR NewswireEWING, N.J. and SAN DIEGO, April 11, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral
- 3y agoONCSOncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesPR NewswireEWING, N.J. and SAN DIEGO, April 10, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral
- 3y agoONCSOncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 TreatmentPR NewswireEWING, N.J. and SAN DIEGO, April 3, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the Company or OncoSec), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate
- 3y agoONCSOncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022PR NewswirePENNINGTON, N.J. and SAN DIEGO, Dec. 5, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing
- 3y agoONCSOncoSec Announces Pricing of $3.5 Million Public OfferingPR NewswirePENNINGTON, N.J. and SAN DIEGO, Nov. 30, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing
- 3y agoONCSOncoSec presents encouraging early data with TAVO™-EP combined with nivolumab (Opdivo®) in neoadjuvant melanomaPR NewswirePENNINGTON, N.J. and SAN DIEGO, Nov. 15, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical stage biotechnology company developing intratumoral
- 4y agoONCSOncoSec Announces Positive Clinical Data of the KEYNOTE-695 Trial Assessing TAVO-EP in Combination with Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma Refractory to anti-PD-1 TreatmentPR NewswirePENNINGTON, N.J. and SAN DIEGO, Nov. 11, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral
- 4y agoONCSOncoSec Announces Reverse Stock SplitPR NewswirePENNINGTON, N.J. and SAN DIEGO, Nov. 8, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing
- 4y agoONCSOncoSec Announces Pipeline Prioritization and Workforce ReductionPR NewswirePENNINGTON, N.J. and SAN DIEGO, Oct. 4, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the patient's own
- 4y agoONCSNovel pre-clinical results regarding OncoSec's intratumoral electroporation platform were highlighted as Editor's Pick in Molecular Cancer ResearchPR NewswireResults demonstrate novel synergistic effects of IL-12 and T cell receptor signaling in anti-tumor immunity PENNINGTON, N.J. and SAN DIEGO, June 24, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinica
- 4y agoONCSOncoSec Receives Triple Negative Breast Cancer Foundation's Vanguard Award for Excellence in Oncology ResearchPR NewswirePENNINGTON, N.J. and SAN DIEGO, May 23, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that it is the recipient of the 2022 Vanguard Award presented by the Triple Negative Breast Cancer (TNBC)
- 4y agoONCSOncoSec Appoints Dr. Robert Arch as President and Chief Executive OfficerPR NewswirePENNINGTON, N.J. and SAN DIEGO, April 29, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the body's immu
- 4y agoONCSOncoSec Announces Appointment of George Chi as Chief Financial OfficerPR NewswirePENNINGTON, N.J. and SAN DIEGO, Feb. 22, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the body's immun
- 4y agoONCSOncoSec Announces Changes to its Board of DirectorsPR NewswirePENNINGTON, N.J. and SAN DIEGO, Dec. 17, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate t
- 5y agoONCSOncoSec Medical Hosting SITC Key Opinion Leader Webinar on Updated Data from the KEYNOTE-695 StudyPR NewswirePENNINGTON, N.J. and SAN DIEGO, Nov. 2, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) will host a conference call and webcast for investors and analysts on Friday, November 12 at 7:00 AM ET featuring key opinion leaders (KOLs) Matteo C
- 5y agoONCSOncoSec Provides Business UpdatePR NewswirePENNINGTON, N.J. and SAN DIEGO, Oct. 20, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate t
- 5y agoONCSOncoSec Provides Leadership UpdatePR NewswirePENNINGTON, N.J. and SAN DIEGO, Aug. 16, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the establishment of a Leadership Committee consisting of three board members, Margaret Dalesandro, Ph.
- 5y agoONCSOncoSec to Participate in Fireside Chat at BTIG Virtual Biotechnology ConferencePR NewswirePENNINGTON, N.J. and SAN DIEGO, July 26, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that Interim CEO and Chief Operating Officer, Brian Leuthner, and Senior Vice President, Chief Clinical
- 5y agoBEAMCVAONCSVTNR+1Thinking about buying stock in Covanta, Vertex Energy, OncoSec Medical, Energous Corp, or Beam Therapeutics?PR NewswireNEW YORK, July 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CVA, VTNR, ONCS, WATT, and BEAM. To
- 5y agoDAREJAGXONCSSEEL+1Thinking about buying stock in OncoSec Medical, Dare Bioscience, Jaguar Health, Americas Gold and Silver, or Seelos Therapeutics?PR NewswireNEW YORK, July 7, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ONCS, DARE, JAGX, USAS, and SEEL. To
- 5y agoONCSOncoSec Enters into a Collaboration Agreement with Merck for a Pivotal Global Phase 3 Study, KEYNOTE-C87, of TAVO™ Combined with KEYTRUDA® for Late-Stage Metastatic MelanomaPR NewswirePENNINGTON, N.J. and SAN DIEGO, July 6, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced it has entered into a Clinical Trial Collaboration and Supply Agreement ("Agreement") with Merck (known a
- 5y agoONCSOncoSec Appoints Brian Leuthner as Interim Chief Executive OfficerPR NewswirePENNINGTON, N.J. and SAN DIEGO, June 24, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that Daniel O'Connor has resigned and that Brian Leuthner, formerly Chief Operating Officer, has been a
- 5y agoONCSOncoSec Appoints Industry Leading Electroporation Device Expert, Jeffrey Silverman, as Vice President of Product EngineeringPR NewswirePENNINGTON, N.J. and SAN DIEGO, June 14, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), today announced the appointment of Jeffrey Silverman as Vice President of Product Engineering, effective June 14, 2021
- 5y agoONCSOncoSec to Present at the Raymond James Human Health Innovation ConferencePR NewswirePENNINGTON, N.J. and SAN DIEGO, May 27, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that management will present a company overview at the Raymond James Human Health Innovation Conference
- 5y agoONCSOncoSec Appoints Robert M. Schinagl, Ph.D. as Vice President of Program and Alliance ManagementPR NewswirePENNINGTON, N.J. and SAN DIEGO, May 17, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the appointment of Robert M. Schinagl, Ph.D., a biotech industry veteran with over 20 years of experienc
- 5y agoONCSOncoSec to Present Encore Interim Data from the KEYNOTE-695 Phase 2b Clinical Trial at the 10th World Congress of MelanomaPR NewswireOncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a biotechnology company focused on cytokine-based intratumoral...
- 5y agoONCSOncoSec Receives CE Mark Certification for its Commercial Electroporation Device "GenPulse™" for the Treatment of Solid TumorsPR NewswireOncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a biotechnology company focused on cytokine-based intratumoral...
- 5y agoONCSOncoSec Medical Sponsoring KOL Webinar On A High Unmet Medical Need: Anti-PD-1 Checkpoint Refractory Metastatic MelanomaPR NewswireOncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a biotechnology company focused on cytokine-based intratumoral cancer...
- 5y agoONCSOncoSec Announces Publication in Clinical Cancer Research of Data Supporting the Therapeutic Potential of Lead Product Candidate, TAVO™, in Triple Negative Breast CancerPR NewswireOncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company focused on cytokine-based intratumoral...
- 5y agoONCSOncoSec Announces Approval of $2.5 Million in NJEDA NOL Program Tax BenefitsPR NewswireOncoSec Medical Incorporated ("OncoSec") (Nasdaq:ONCS), a late-stage biotechnology company focused on designing, developing and commercializing...
- 5y agoONCSOncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical DevelopmentPR NewswireOncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the appointment of Bridget O'Keeffe, Ph.D., a biotech...
- 5y agoONCSOncoSec Strengthens Management Team With Two New AppointmentsPR NewswireOncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the addition of two new executives to the company's...
- 5y agoONCSOncoSec Announces First Subjects Dosed in Phase 1 Trial of CORVax12, OncoSec's COVID-19 Vaccine Candidate Combining Interleukin-12 (IL-12) with an Enhanced SARS-CoV-2 Spike ProteinPR NewswireOncoSec Medical Incorporated (NASDAQ: ONCS) today announced that it has dosed several subjects in its Phase 1 clinical trial of CORVax12, the only...
- 5y agoONCSOncoSec Medical Closes $42.0 Million Public Offering of Common StockPR NewswireOncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company focused on designing, developing and...
- 5y agoONCSOncoSec Medical Announces Pricing of $42.0 Million Public Offering of Common StockPR NewswireOncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company focused on designing, developing and...
- 5y agoONCSOncoSec Medical Announces Proposed Public Offering of Common StockPR NewswireOncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company focused on designing, developing and...
- 5y agoONCSSirtex Medical announces collaboration update with OncoSec MedicalPR NewswireSirtex Medical US Holdings, Inc. ("Sirtex"), a leading manufacturer of targeted cancer therapies, announced an advancement in its strategic...
- 5y agoONCSOncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO™PR NewswireOncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced it entered into an agreement with Sirtex Medical, Inc....
- 5y agoONCSOncoSec Announces First Patient Dosed in Phase 2 Trial of TAVO™ Plus OPDIVO® as Neoadjuvant Therapy for MelanomaPR NewswireOncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the first patient was dosed in OMS-104, an...
- 5y agoONCSOncoSec Strengthens IP Portfolio with Allowance of Two European Patent Applications Covering TAVO™ and Its Gene Electrotransfer TechnologyPR NewswireOncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that the European Patent Office has issued notices of...
- 5y agoONCSOncoSec Announces Publication in International Journal of Surgery Case ReportsPR NewswireOncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company developing intratumoral cancer...
- 5y agoONCSOncoSec Announces Exclusive License Agreement for Cliniporator® Gene Electrotransfer Platform Developed by IGEA Clinical BiophysicsPR NewswireOncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company developing intra-tumoral cancer...
- 5y agoONCSOncoSec Provides Highlights from Analyst & Investor Day and SITC 2020 and Announces KEYNOTE-695 Reaches Full EnrollmentPR NewswireOncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today provided highlights from its Analyst & Investor Day and Symposium held...
- 5y agoONCSCORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2) - NCT04627675ClinicalTrials.govToxicity, Medically Attended Adverse Events (MAAEs)
- 6y agoONCSOncoSec Announces Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma at SITC 2020PR NewswireOncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced new positive interim data from its KEYNOTE-695...
- 6y agoONCSOncoSec Hosting an Investor and Analyst Day Webinar Showcasing Positive KEYNOTE-695 Data in Anti-PD-1 Checkpoint Refractory Metastatic MelanomaPR NewswireOncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that it will host an Investor and Analyst webinar on...